Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 203

1.

Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy.

Verstovsek S, Harrison CN, Kiladjian JJ, Miller C, Naim AB, Paranagama DC, Habr D, Vannucchi AM.

Leuk Res. 2017 Jan 31;56:52-59. doi: 10.1016/j.leukres.2017.01.032. [Epub ahead of print]

PMID:
28193568
2.

Bioequivalence Studies of a Reformulated Dutasteride and Tamsulosin Hydrochloride Combination Capsule and a Commercially Available Formulation.

Kurczewski R, Bowen C, Collins D, Zhu J, Serbest G, Manyak M.

Clin Pharmacol Drug Dev. 2017 Jan 27. doi: 10.1002/cpdd.334. [Epub ahead of print]

PMID:
28127948
3.

First-in-Human Phase 1 Study of the Oral Inhibitor of Indoleamine 2,3-dioxygenase-1 Epacadostat (INCB024360) in Patients With Advanced Solid Malignancies.

Beatty GL, O'Dwyer PJ, Clark J, Shi JG, Bowman KJ, Scherle P, Newton RC, Schaub R, Maleski J, Leopold L, Gajewski TF.

Clin Cancer Res. 2017 Jan 4. pii: clincanres.2272.2016. doi: 10.1158/1078-0432.CCR-16-2272. [Epub ahead of print]

PMID:
28053021
4.

Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies.

Shi JG, Bowman KJ, Chen X, Maleski J, Leopold L, Yeleswaram S.

J Clin Pharmacol. 2016 Dec 19. doi: 10.1002/jcph.855. [Epub ahead of print]

PMID:
27990653
5.

Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody.

Dominguez G, Condamine TC, Mony S, Hashimoto A, Wang F, Liu Q, Forero A, Bendell JC, Witt R, Hockstein N, Kumar P, Gabrilovich D.

Clin Cancer Res. 2016 Dec 13. pii: clincanres.1784.2016. [Epub ahead of print]

PMID:
27965309
6.

The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).

Mesa R, Vannucchi AM, Yacoub A, Zachee P, Garg M, Lyons R, Koschmieder S, Rinaldi C, Byrne J, Hasan Y, Passamonti F, Verstovsek S, Hunter D, Jones MM, Zhen H, Habr D, Martino B.

Br J Haematol. 2017 Jan;176(1):76-85. doi: 10.1111/bjh.14382.

7.

2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 2 - Hybrid LBA/LCMS and input from regulatory agencies).

Song A, Lee A, Garofolo F, Kaur S, Duggan J, Evans C, Palandra J, Donato LD, Xu K, Bauer R, Bustard M, Chen L, Cocea L, Croft S, Galliccia F, Haidar S, Hughes N, Ishii-Watabe A, Islam R, Jones B, Kadavil J, Krantz C, Lima Santos GM, Olah T, Pedras-Vasconcelos J, Staelens L, Saito Y, Savoie N, Scheibner K, Spitz S, Tampal N, Thomas E, Vinter S, Wakelin-Smith J, Welink J, Zeng J, Zhou S.

Bioanalysis. 2016 Dec;8(23):2457-2474.

8.

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.

Mascarenhas JO, Talpaz M, Gupta V, Foltz LM, Savona MR, Paquette R, Turner AR, Coughlin P, Winton E, Burn TC, O'Neill P, Clark J, Hunter D, Assad A, Hoffman R, Verstovsek S.

Haematologica. 2017 Feb;102(2):327-335. doi: 10.3324/haematol.2016.151126.

9.

Results from oral gavage carcinogenicity studies of ruxolitinib in Tg.rasH2 mice and Sprague-Dawley (Crl:CD) rats.

Shuey DL, Oliver J, Zhou G, Roberts A.

Regul Toxicol Pharmacol. 2016 Nov;81:305-315. doi: 10.1016/j.yrtph.2016.09.016.

PMID:
27647628
10.

Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.

Pulford DJ, Harter P, Floquet A, Barrett C, Suh DH, Friedlander M, Arranz JA, Hasegawa K, Tada H, Vuylsteke P, Mirza MR, Donadello N, Scambia G, Johnson T, Cox C, Chan JK, Imhof M, Herzog TJ, Calvert P, Wimberger P, Berton-Rigaud D, Lim MC, Elser G, Xu CF, du Bois A.

BMC Med Ethics. 2016 Oct 21;17(1):63.

11.

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.

Jochems C, Fantini M, Fernando RI, Kwilas AR, Donahue RN, Lepone LM, Grenga I, Kim YS, Brechbiel MW, Gulley JL, Madan RA, Heery CR, Hodge JW, Newton R, Schlom J, Tsang KY.

Oncotarget. 2016 Jun 21;7(25):37762-37772. doi: 10.18632/oncotarget.9326.

12.

Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.

Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Naim A, Parasuraman S, Boyle J, Mascarenhas JO.

Cancer. 2017 Feb 1;123(3):449-458. doi: 10.1002/cncr.30325.

PMID:
27690182
13.

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.

Gupta V, Harrison C, Hexner EO, Al-Ali HK, Foltz L, Montgomery M, Sun W, Gopalakrishna P, Kantarjian H, Verstovsek S.

Haematologica. 2016 Dec;101(12):e482-e484. No abstract available.

14.

Roles of UGT, P450, and Gut Microbiota in the Metabolism of Epacadostat in Humans.

Boer J, Young-Sciame R, Lee F, Bowman KJ, Yang X, Shi JG, Nedza FM, Frietze W, Galya L, Combs AP, Yeleswaram S, Diamond S.

Drug Metab Dispos. 2016 Oct;44(10):1668-74. doi: 10.1124/dmd.116.070680.

PMID:
27457784
15.

Scientific and Regulatory Policy Committee Points to Consider Review: Inclusion of Reproductive and Pathology End Points for Assessment of Reproductive and Developmental Toxicity in Pharmaceutical Drug Development.

Halpern WG, Ameri M, Bowman CJ, Elwell MR, Mirsky ML, Oliver J, Regan KS, Remick AK, Sutherland VL, Thompson KE, Tremblay C, Yoshida M, Tomlinson L.

Toxicol Pathol. 2016 Aug;44(6):789-809. doi: 10.1177/0192623316650052.

PMID:
27235322
16.

Evaluation of the utility of popliteal lymph node examination in a cyclophosphamide model of immunotoxicity in the rat.

Lapointe JM, Valdez RA, Ryan AM, Haley PJ.

J Immunotoxicol. 2016 Jul;13(4):449-52. doi: 10.3109/1547691X.2015.1122117.

PMID:
27216540
17.

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T.

Leukemia. 2016 Aug;30(8):1701-7. doi: 10.1038/leu.2016.148.

PMID:
27211272
18.

Licensure in the Era of Genomic Medicine.

Park JY, Leung ST, Wang J.

Arch Pathol Lab Med. 2016 Jul;140(7):623-4. doi: 10.5858/arpa.2016-0103-ED. No abstract available.

PMID:
27139151
19.

Structural diversity of xylans in the cell walls of monocots.

Peña MJ, Kulkarni AR, Backe J, Boyd M, O'Neill MA, York WS.

Planta. 2016 Sep;244(3):589-606. doi: 10.1007/s00425-016-2527-1.

PMID:
27105886
20.

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.

Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Moiraghi B, Miller CB, Cazzola M, Rosti V, Blau I, Mesa R, Jones MM, Zhen H, Li J, Francillard N, Habr D, Kiladjian JJ.

Haematologica. 2016 Jul;101(7):821-9. doi: 10.3324/haematol.2016.143644.

Items per page

Supplemental Content

Loading ...
Support Center